Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing
Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Related

Vinge has advised Terranor Group AB in connection with its listing on Nasdaq First North Growth Market

 Vinge has advised Terranor Group AB (publ) (“Terranor”) connection with its listing on Nasdaq First North Growth Market. The first day of trading in Terranor's shares is today 30 June 2025.
June 30, 2025

Vinge advises Keyto Group in connection with the acquisition of GreenThumb

KEYTO Group expands into the UK market as GreenThumb joins the group. This partnership marks KEYTO’s first entry in the UK and reinforces its ambition to build the leading, tech-enabled one-stop destination for home-related services internationally.
June 30, 2025

Vinge advises Odevo in the acquisition of Portik Group

 Vinge has advised Odevo, the internationally leading company within residential property management, in connection with the acquisition of Portik Group. Through the acquisition, Odevo continues its international expansion by establishing itself in Spain, Italy, Portugal and Mexico.
June 27, 2025